Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective

被引:1
|
作者
Rathod, Reena J. [1 ]
Sukumaran, Reghu K. [2 ]
Kedia, Neelam [1 ]
Kumar, Jeevan [2 ]
Nair, Reena [2 ]
Chandy, Mammen [2 ]
Gandikota, Lakshmikanth [1 ]
Radhakrishnan, Vivek Sulekha [2 ]
机构
[1] Intas Pharmaceut, Cell & Gene Therapy Div, Ahmadabad, Gujarat, India
[2] Tata Med Ctr, Hematol Oncol & HCT, Kolkata, W Bengal, India
关键词
Chimeric antigen receptor; T-cell; CAR-T; cellular therapy; cancer; India; B-CELL; CD19; IMMUNOTHERAPY; EXPANSION; TISAGENLECLEUCEL; MALIGNANCIES; LYMPHOCYTES; IDEC-C2B8; ANTI-CD20; LYMPHOMA;
D O I
10.4103/ijc.ijc_433_21
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Using one's own immune system for curing cancer has been an active field of research in cancer biology and therapeutics. One such opportunity in cellular immunotherapy is adoptive cell transfers. With the recent approval of CAR-T therapy as a cancer treatment, a whole new paradigm of cancer treatment has opened-up, with a ray of hope for relapsed/refractory cancer patients. Despite promising clinical outcomes, the therapy is in its early phase and remains out of reach for most patients due to its high cost and logistic challenges. In India, these therapies are unavailable and further confounded by the economic challenges and a large population. In this review, we discuss various aspects of T-cell immunotherapies with a special focus on CAR-T in the Indian scenario. We touch upon the basic scientific aspects, mechanism of action, manufacturing, clinical aspects and commercial aspects of the CAR-Tcell therapies and its future worldwide and in India.
引用
收藏
页码:204 / 214
页数:11
相关论文
共 50 条
  • [1] Chimeric antigen receptor T-cell therapies for lymphoma
    Brudno, Jennifer N.
    Kochenderfer, James N.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (01) : 31 - 46
  • [2] Chimeric antigen receptor T-cell therapies for lymphoma
    Jennifer N. Brudno
    James N. Kochenderfer
    Nature Reviews Clinical Oncology, 2018, 15 : 31 - 46
  • [3] Chimeric Antigen Receptor T-Cell Therapies Advancing
    Brower, Vicki
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (11):
  • [4] Chimeric antigen receptor T-cell therapies: Optimising the dose
    Dasyam, Nathaniel
    George, Philip
    Weinkove, Robert
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (09) : 1678 - 1689
  • [5] Chimeric antigen receptor T-cell therapies for multiple myeloma
    Mikkilineni, Lekha
    Kochenderfer, James N.
    BLOOD, 2017, 130 (24) : 2594 - 2602
  • [6] An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
    Feins, Steven
    Kong, Weimin
    Williams, Erik F.
    Milone, Michael C.
    Fraietta, Joseph A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S3 - S9
  • [7] HEALTH TECHNOLOGY ASSESSMENT FOR CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR CANCER
    Hollier-Hann, G.
    Brown, A.
    Ralston, S.
    Curry, A.
    Cork, D.
    VALUE IN HEALTH, 2018, 21 : S65 - S65
  • [8] Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies
    Polgarova, Kamila
    Otahal, Pavel
    Salek, Cyril
    Pytlik, Robert
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Infectious complications of chimeric antigen receptor (CAR) T-cell therapies
    Gea-Banacloche, Juan C.
    SEMINARS IN HEMATOLOGY, 2023, 60 (01) : 52 - 58
  • [10] Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
    Alsajjan, Roa
    Mason, Warren P.
    CURRENT ONCOLOGY, 2023, 30 (09) : 8501 - 8549